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Abstract
Mutations in the collagen genes COL4A1 and COL4A2 cause Mendelian eye, kidney and cerebrovascular disease including
intracerebral haemorrhage (ICH), and common collagen IV variants are a risk factor for sporadic ICH. COL4A1 and COL4A2
mutations cause endoplasmic reticulum (ER) stress and basement membrane (BM) defects, and recent data suggest an
association of ER stress with ICH due to a COL4A2 mutation. However, the potential of ER stress as a therapeutic target for
the multi-systemic COL4A1 pathologies remains unclear. We performed a preventative oral treatment of Col4a1 mutant
mice with the chemical chaperone phenyl butyric acid (PBA), which reduced adult ICH. Importantly, treatment of adult mice
with the established disease also reduced ICH. However, PBA treatment did not alter eye and kidney defects, establishing
tissue-specific outcomes of targeting Col4a1-derived ER stress, and therefore this treatment may not be applicable for
patients with eye and renal disease. While PBA treatment reduced ER stress and increased collagen IV incorporation into
BMs, the persistence of defects in BM structure and reduced ability of the BM to withstand mechanical stress indicate that
PBA may be counter-indicative for pathologies caused by matrix defects. These data establish that treatment for COL4A1
disease requires a multipronged treatment approach that restores both ER homeostasis and matrix defects. Alleviating ER
stress is a valid therapeutic target for preventing and treating established adult ICH, but collagen IV patients will require
stratification based on their clinical presentation and mechanism of their mutations.
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Introduction
Diseases caused by mutations in extracellular matrix compo-
nents are traditionally considered matrix diseases, but many
mutations elicit intracellular consequences (1). This has gener-
ated increasing interest in delineating the role of these intracel-
lular responses in pathology and their potential as a therapeutic
target. The basement membrane (BM) is an extracellular matrix
structure that provides structural support, compartmentalizes
tissues and influences cell behaviour and signalling (2). Collagen
IV is a major BM component, and in vertebrates, the genes
COL4A1–COL4A6 encode six collagen IV alpha chains [α1(IV)–
α6(IV)]. These alpha chains assemble into three networks,
α1α1α2(IV), α3α4α5(IV) and α5α5α6(IV), of which is α1α1α2(IV)
is the most widely expressed (3). COL4A1/COL4A2 mutations
cause a multi-systemic disorder encompassing cerebrovascular
disease, including intracerebral haemorrhage (ICH), as well as
eye and renal defects (4–7) including HANAC syndrome (8,9).
The variability in clinical presentation and severity means not
every patient develops eye or kidney pathology in addition to
cerebrovascular disease (7,10). The identification of rare mutat-
ions in sporadic haemorrhaging (11,12), and that common
COL4A2 variants are a risk factor for deep ICH (13) and
white matter hyperintensities (14) in the general population,
underscore an important role for COL4A1/COL4A2 in common
cerebrovascular disease and ICH. ICH accounts for 15% of adult
stroke and 50% of paediatric stroke (15), and besides generic
risk-reducing approaches, there are no specific treatments.
Mouse models with Col4a1 missense mutations such
as Col4a1+/SVC are excellent tools to investigate therapeutic
strategies. They display ICH (4,16,17), eye disease including
anterior segment dysgenesis (ASD) (18–20) and renal disease
including Bowman’s capsule defects and tubular dysfunction
(18,21,22). Col4a1+/SVC mice harbour a glycine to aspartic acid
mutation affecting a highly conserved glycine residue of the Gly-
X-Y repeat in the collagen domain of α1(IV) (18,22), equivalent to
the vast majority (> 85%) of COL4A1/COL4A2 mutations.
There are no treatments for diseases caused by COL4A1/
COL4A2 mutations, and the disease mechanisms remain poorly
understood. Endoplasmic reticulum (ER) stress has emerged as
a potential disease mechanism in addition to matrix defects for
mutations in matrix components including collagen (1). Besides
ECM defects, collagen IV mutations can lead to intracellular
accumulation of collagen IV and ER stress (17,18,23,24). Genetic
evidence from a family with a COL4A2 mutation indicated that
ER retention of α1α1α2(IV) and subsequent ER stress is asso-
ciated with porencephaly and ICH (25), which was supported
by animal data (26). ER stress due to ER retention of secreted
protein elicits the unfolded protein response that entails three
signalling arms: cleavage of XBP1 by IRE-1, proteolytic cleavage
of ATF6 and phosphorylation of eIf2α causing the upregulation
of ATF4 (27). ER stress has been observed in a wide spectrum of
diseases such as (cerebro) vascular, renal (28–30) and ocular (31),
pathologies, including age-related disease (32), but for many of
these disorders, including adult ICH, its potential as therapeutic
target remain unclear. Interestingly, ER stress can be targeted
using compounds including 4-sodium phenyl butyrate (PBA), an
FDA-approved chemical chaperone (33).
Here, we set out to determine the efficacy of PBA as a treat-
ment for adult COL4A1/4A2 pathologies. Our data establish that
reducing ER stress is a therapeutic avenue for preventing and
treating established adult ICH, but is not for effective eye and
renal pathologies and can be counter-indicative for patholo-
gies due to BM defects as it reduces their ability to withstand
mechanical stress. This highlights the need for patient stratifica-
tion for such treatment approaches based on both their clinical
presentation and knowledge of the underlying mechanism of
their specific mutations.
Results
Targeting ER stress as a preventative treatment for ICH
As defects due to COL4A1 mutations can present in childhood,
a therapeutic approach will likely be long-term and would
preferentially be orally administered. Tomodel this preventative
treatment, we treated Col4a1+/SVC mice (18,34) orally with PBA
from conception, by treatment of pregnant dams, and ICH
was determined in 5-month-old adult mice, treated daily
(Fig. 1A). Magnetic resonance imaging (MRI) of the midbrain
revealed that most ICH is centred towards the basal ganglia
and, importantly, a ∼50% reduction in bleed volume of PBA-
treated Col4a1+/SVC mice (Fig. 1B and C). As PBA did not affect the
number of haemorrhages, this reduced severity is obtained by
modulating bleed volume (Fig. 1C). Histopathological analysis
using Prussian blue stain for hemosiderin (Perl’s staining)
confirmed the MRI data (Fig. 1D and E). Col4a1+/SVC display
increased levels of Iba1, a marker for neuroglial activation that
is the initial step in the central nervous system inflammatory
response following stroke (35), which was reduced in treated
mice (Fig. 1F and G), supporting reduced cerebrovascular
disease severity and neuroinflammation. Tail cuff plethysmo-
graphy revealed no significant change in systolic blood pressure
in mutant mice (Supplementary Material, Fig. S1), indicating
the reduction in ICH is not dependent on altered vascular
haemostasis.
Modification of eye and renal defects
Col4a1 renal disease encompasses glomerular defects including
hypertrophy of Bowman’s capsule and glomerulocystic kidney
disease (18,21,22), as well as tubular defects that are associated
with polyuria (increased urine production) (22). Preventative PBA
treatment reduced polyuria (Fig. 2A). However, both untreated
and treated mice displayed defects of the parietal epithelium in
Bowman’s capsule with a cuboidal appearance of epithelial cells,
suggestive of epithelial cell activation (21) (Fig. 2B), and/or for-
mation of multiple cell layers (18,21,22): ∼74% (75/102) and ∼73%
(70/96) of Bowman’s capsules of untreated and treated mice,
respectively (Fig. 2B, C and E). Col4a1 glomerulocystic kidney
disease includes retraction of the capillary tuft (21), which was
detected in ∼18% (19/103) of glomeruli in untreated mice and
∼15% (14/94) of treated mice (Fig. 2B, D and F). The occurrence
of capillary tuft retraction in Col4a1+/SVC appears to occur in
glomeruli that do not appear to exhibit the parietal epithelial cell
defect (Fig. 2B). Evidence of atrophy of themedulla also remained
(Supplementary Material, Fig. S2B). These data indicate a dif-
ferential response whereby Bowman’s capsule and glomerular
defects are recalcitrant to PBA treatment while polyuria appears
reduced.
In the eye, Col4a1 mutations can lead to ASD encompassing
corneal clouding, cataracts, iris hypoplasia and buphthalmos
(enlargement of the anterior chamber) on slit lamp examination
(Fig. 2I) (5,18,20). PBA-treated and untreated mice showed iris–
corneal adhesions, dysgenic ciliary body and reduced or absence
of trabecularmeshwork (Fig. 2G andH). Severity scoring revealed
PBA treatment did not alter ASD severity (Fig. 2H), while slit
lamp analysis revealed iris hypoplasia, corneal clouding and
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Figure 1. PBA reduces ICH. (A) Overview of preventative PBA treatment from conception to point of analysis. (B) MRI image of untreated and treated small with vacuolar
cataracts (SVC) mice showing ICH (red arrow). (C) Image analysis of MRI data reveals reduced ICH bleed volume (left graph) but not ICH number of bleeds (right graph)
(WT n = 6, SVC n = 10, SVC PBA n = 6). (D) Perl’s staining of brains from 5-month-old untreated Col4a1+/SVC and Col4a1+/SVC treated from conception (blue staining).
(E) Image analysis of Perl’s staining ICH (WT n = 7, SVC n = 6, SVC PBA n = 12). (F) Immunostaining against Iba1 (brown) on brain sections with detail of dashed square
provided in a small square. (G) ImageJ analysis of staining is provided in graph (WT n = 6, SVC n = 5, SVC PBA n = 3). One-way analysis of variance (ANOVA) with post
hoc test [Bonferroni (G), Tukey (E); ∗ P-value < 0.05; ∗∗∗ P-value < 0.001].
neovascularisation in treated and untreated mice (Fig. 2I and J).
The inner and outer retinal nuclear layers in Col4a1+/SVC can
appear disorganized (Supplementary Material, Fig. S3B) and
optic nerve cupping remains present following PBA treatment
(Supplementary Material, Fig. S3D).
Investigating the efficacy of PBA treatment on
established phenotypes
Treatment from conception or birth provides a proof-of-principle
preventative approach that would only be possible for some
familial cases. In most cases treatment will occur post ICH
and molecular diagnosis. We therefore treated a 4-month-old
Col4a1+/SVC for 1 month to determine if PBA can reduce estab-
lished disease (Fig. 3A). While ICH severity was maintained on
MRI analysis (Fig. 3B and C), ICH was significantly reduced based
on histopathology using Perl’s stain (Fig. 3D and E). It should be
taken into account that the resolution of our MRI analysis is not
sufficient to detect microbleeds. Therefore, our data establishes
that PBA can reduce established adult cerebrovascular pheno-
types and suggests that PBA mainly affects small microbleeds
not detectable with MRI.
Slit lamp analysis and histopathology did not reveal amelio-
ration of ASD following treatment (Fig. 3F and G). Histopatholog-
ical analysis of the retina did show a trend towards reduced optic
nerve ‘cupping’, which in Col4a1mutant mice reflect optic nerve
hypoplasia (23), but signs of retinopathy were also observed
(Supplementary Material, Fig. S3C and D). In the kidney, defects
in the parietal epitheliumof Bowman’s capsule occurred in∼74%
(86/116) Bowman’s capsules (Fig. 3H), and cystic changes in ∼5%
(6/116) glomeruli (Fig. 3I), compared to 74% and 18% in untreated
mice, while polyuria (Supplementary Material, Fig. S2) was also
observed. Thus, in our hands PBA has very limited efficacy for
eye and glomerular renal phenotypes both as a preventative
measure and treatment approach.
PBA reduces ER stress and increases deposition of
collagen IV in the BM
To determine if PBA was able to reduce ER stress levels in vivo,
we assessed protein levels of ER stress markers Bip and Atf4 in
kidney of adult Col4a1+/SVC mice treated from conception, which
revealed a significant reduction in their levels (Fig. 4A and B).
Reduced ER stress was also observed in mice treated for
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Figure 2. Effect of PBA treatment on adult eye and renal defects. (A) Daily urine output of five-month-old untreated WT littermate, untreated Col4a1+/SVC mice
and treated Col4a1+/SVC (WT n = 20, SVC n = 18, SVC PBA n = 6). (B) Haematoxylin and eosin staining of kidneys revealed in untreated Col4a1+/SVC (SVC) and PBA-
treated Col4a1+/SVC mice (SVC PBA) defects (cuboidal appearance, formation of multiple cell layers) of parietal epithelial cells of Bowman’s capsule (black arrow) and
glomerulocystic kidney disease (retraction of vascular tuft, green arrow). SVC: untreated Col4a1+/SVC . (n = 4). (C) Image analysis of Bowman’s capsules in WT (n = 75
capsules) and Col4a1+/SVC (n= 102) (χ2 = 42.52; 1 df). (D) Image analysis of glomerulocystic kidney disease inWT (n= 75 glomeruli) and Col4a1+/SVC (n= 102) (χ2 = 15.49;
1 df). (E) Image analysis reveals similar frequency of Bowman’s capsule defects in treated (n= 84) and untreated (n= 102) Col4a1+/SVC . (χ2 = 0.009; 1 df) (F) Image analysis
reveals similar frequency of cystic defects in treated (n = 103 glomeruli) and untreated (n = 94) Col4a1+/SVC (χ2 = 0.44; 1 df). (G) Haematoxylin and eosin staining of eyes
revealed persistence of ASD defects in treated mice (SVC PBA) including iridocorneal adhesion (arrow), atrophy of the ciliary body (∗) size bar = 50 μm. (H) Scoring of
anterior segment (presence/absence of iridocorneal adhesion, ciliary body morphology, presence/absence of open Shlemm’s canal) in WT, untreated (SVC) and treated
mutant (SVC + PBA) mice. (WT n = 4, SVC n = 4, SVC PBA n = 6 mice). (I) Slit lamp analysis revealed persistence of opacity of the cornea (scoring system applies only
to corneal opacity) and iris hypoplasia in treated mice. Corneal neovascularization (see ‘severe’ panel) is also observed. The right panel is the graphical representation
of the scoring of corneal opacity. (SVC n = 6, SVC PBA n = 4 animals). (J) Image analysis of corneal opacity scoring. (C)–(F): Two-sided chi-square test; (A), (H): One-way
ANOVA post hoc Sidak test ∗P-value<0.05, ∗∗∗∗P-value <0.0001.
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Figure 3. PBA treatment of established disease. (A) Diagram of 1-month oral PBA treatment for the treatment of established phenotypes in 5-month-old mice. (B) MRI
image of a mutant animal pre and post treatment reveals ICH (black arrow). (C) ImageJ analysis of MRI data based on bleed number (top) and bleed volume (bottom)
(SVC n = 11, SVC PBA n = 8). (D) Perl’s staining of brains sections reveals ICH (blue staining) untreated and treatedmutantmice (SVC and SVC 1M PBA). (E) Image analysis
indicating percentage of tissue that stained positive for ICH (n = 3). (F) Slit lamp analysis reveals persistence of corneal opacity and iris hypoplasia. The images are of
the same eye of the animal pre and post treatment (n = 4 animals). (G) Scoring of anterior segment (presence/absence of iridocorneal adhesion, ciliary bodymorphology,
presence/absence of open Shlemm’s canal) in untreated (SVC) and treated Col4a1+/SVC (SVC 1M PBA). (SVC n= 4, SVC 1M PBA n= 4mice) (H) Image analysis of Bowman’s
capsule defects in untreated and treatedmice (n = 116). (I) Image analysis of glomerulocystic defects (χ2 = 9.506; 1 df, P = 0.002). (Histopathology of the eye and kidney is
provided in SupplementaryMaterial, Figs S2 and S3). (D), (E) One-way ANOVAwith Bonferonni post hoc test; (F) Two-sided chi-square ∗P-value < 0.05, ∗∗∗P-value < 0.001.
1 month (Supplementary Material, Fig. S4). To further illuminate
the mechanism of PBA we performed immunostaining against
Col4a1 on kidney sections as kidney contains vascular, epithelial
and glomerular BMs (GBMs). Both lifelong and 1-month PBA
treatment increased staining of Col4a1 within the BMs (Fig. 4C
and D), indicating that the reduced ER stress is coupled with
increased secretion and staining of collagen IV in the BM. The
absence of increased staining of collagen IV in lifelong versus
1-month treatments also suggests that long-term chemical
chaperone treatment may not have additional long-term
improvement/restoration of collagen IV deposition within the
BM compared to a shorter treatment. Besides being a chemical
chaperone PBA can also inhibit histone de-acetylation activity,
which could lead to the increased transcription of collagen IV.
Quantitative reverse trancription polymerase chain reaction
(qRT-PCR) analysis on mRNA samples from kidneys from
untreated and lifelong treated mice revealed that PBA did not
alter collagen IV mRNA levels (Supplementary Material, Fig. S5),
supporting that the increased collagen IV staining is due to the
chemical chaperone activity of PBA.
Effects of chemical chaperone on BM structure function
To determine if increased collagen IV deposition alters BM struc-
tureweperformed transmission electronmicroscopy (EM) analy-
sis of kidney,which enables analysis of vascular, endothelial and
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Figure 4. Chemical chaperone activity increases deposition of collagen IV in vivo. (A) Western blotting showed increased levels of Bip (∼2.9-fold increase) and ATF4
(∼4.6-fold increase) in untreated Col4a1+/Svc (SVC unt) which is reduced following PBA treatment. Representative band of total protein stain is given as loading control
(the entire gel is provided in SupplementaryMaterial, Fig. S9). (B) ImageJ densitometry analysis of Bip and ATF4 (n= 3). (C) Immunostaining against Col4a1 in PBA-treated
and untreated Col4a1+/Svc mice (WT: wild-type; SVC: untreated; SVC 1M PBA: 1-month treatment; SVC LL PBA: lifelong chronic treatment from conception) on kidney
sections revealed increased deposition of Col4a1 following PBA treatment. (n = 3–5 mice, Bowman’s capsule: SVC n = 30, SVC 1 M PBA n = 42, SVC LL PBA n = 16; Tubular
BM SVC n = 89, SVC 1M PBA n = 77, SVC LL PBA n = 47; Vascular BM SVC n = 36, SVC 1M PBA n = 23, SVC LL PBA n = 15). (D) ImageJ analysis of fluorescence staining. (B),
(D) One-way ANOVA post hoc Sidak test ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
epithelial BMs. In wild-type (WT) mice, PBA did not alter colla-
gen IV deposition (Supplementary Material, Fig. S6). In mutant
mice, despite increased collagen IV staining (Fig. 4E), PBA did
not affect mean thickness of renal and vascular BMs (VBMs)
(Supplementary Material, Fig. S7A–D), but BMs were character-
ized by a large variation in thickness (Supplementary Material,
Fig. S7C and D). EM analysis revealed that PBA treatment did
not affect tubular BM structure (Fig. 5A), which is unaffected in
Col4a1+/SVC mice (Fig. 5A) and (22). However, we did occasion-
ally observe small focal duplications in some animals (1-month
treatment: 1/4 animals; lifelong treatment: 2/5 animals) (Supple-
mentary Material, Fig. S7E). Defects in BM of Bowman’s capsule
included an irregular appearance, lamellation and multiple lay-
ers, as observed for untreated Col4a1 mutant mice [Fig. 5B and
(18,22)]. Although the overall reduction of ER stress levels was
observed, some treated animals displayed more prominent ER
vesicles in parietal epithelial cells of Bowman’s capsule (Fig. 5B).
The GBM of treated and untreated animals was similar with
irregular GBM thickness [Fig. 5C and (22)], but average thick-
ness remained unchanged (Supplementary Material, Fig. S7C).
However, PBA treatment appears to result in a reduction in
the variability of GBM thickness (Supplementary Material, Fig.
S7C). The vascular BM revealed heterogeneity whereby the BM
in treated animals appeared in some sections more continu-
ous compared to untreated mice (Fig. 5D). However, significant
areas of apparent BM absence, disruptions and diffuse BMs with
reduced electron density were also observed. Both treated and
untreated Col4a1+/SVC mice showed fibrillar collagen deposition
(Fig. 5D). Taken together these data indicate that PBA treatment
does not significantly improve BM ultrastructure.
Given the increased deposition of collagen IV into the BM,
we investigated if this affected BM strength. The dermal BM is
critical for the adhesion of the epidermis to the dermis, and
dermal BM defects cause blister formation in epidermolysis bul-
losa (36). Tape stripping on the back skin of mice generates mild
mechanical stress, which enables a measurement of the ability
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Figure 5. Effect of PBA on BM structure. (A) Normal appearance of BM of tubules (white arrow) in untreated Col4a1+/SVC (SVC) and mice treated for 1 month at
4 months of age (SVC 1M PBA) or from conception for 5 months (SVC LL PBA). (B) Severe defects in BM of Bowman’s capsule in all mice including bulges (white arrow
SVC), basket weave appearance (white arrow SVC 1M PBA) andmultiple layers (white arrow SVC LL PBA). Evidence of enlarged ER (red arrow SVC 1M PBA) and increased
vesicles (red arrow SVC LL PBA) is also observed. (C) Irregular thickening (white arrow) of GBM in treated and untreated mice. Thinner BM areas are also observed (black
arrow). (D) VBM defects include interruption (white arrow SVC, 1M PBA), presence of collagen fibrils (white arrow bottom panel 1 M PBA) andmore fuzzy but continuous
BM (bottom panel LL PBA) black size bar 1 μm, white size bar 5 μm. One-way ANOVA post hoc Tukey test ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Figure 6. PBA does not improve BM strength. (A) PAS stain of tissue section from Col4a1+/SVC and 1-month treated Col4a1+/SVC (SVC PBA), which shows separation
of dermis from epidermis (circle). (B) ImageJ analysis revealed increased separation in treated mice (SVC n = 7, SVC PBA n = 4) unpaired t-test ∗P < 0.05 (Stain of WT
littermate is provided in Supplementary Material, Fig. S8).
of the BM to withstand separation of the dermis from the epider-
mis and blister formation (37). We employed this tape stripping
procedure followed by periodic acid–Schiff (PAS) staining (Fig 6A)
to assess the ability of the BM to withstand mechanical stress
as a measure of its strength. Compared to WT, Col4a1+/SVC
showed increased separation of dermis from the epidermis,
indicating a weaker BM (Supplementary Material, Fig. S8).
Surprisingly, PBA did not reduce the level of separation, but
apparent increased severity was observed (Fig. 6B). These results
provide evidence that increased collagen IV secretion in mutant
mice and chemical chaperones can reduce the ability of BMs to
withstand mechanical strength.
Discussion
Disorders due to mutations in BM and matrix components
are rare diseases and for most of these diseases treatment
remains a long-term goal. Specific treatments are often also
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lacking for common diseases including haemorrhagic stroke
that accounts for 15% of adult stroke and is a major burden on
society (15). Developing specific or more effective treatments is
underpinned by understanding disease mechanisms. Mutations
in COL4A1/COL4A2 cause ER stress and BM defects (10,22,25)
and while ER stress occurs in a large number of diseases,
including extracellular matrix disorders (1,38), the efficacy of
targeting ER stress as a long-term therapeutic approach for
adult onset diseases, either as preventative approach or as
treatment of existing conditions, is an important question
to address. Mutations in ECM and BM components most often
result in complex multi-systemic diseases (36). Therefore,
it is important to adopt a holistic approach and determine
the efficacy of compounds across a spectrum of affected
tissues.
We performed a chemical chaperone treatment to target
ER stress in mice carrying a Col4a1 glycine missense mutation,
the most common mutation type identified in patients (39).
While ICH due to COL4A1/COL4A2mutations can occur through-
out life (4,6,17,19,36,40), many of the vascular and extra-vascular
pathologies, including renal and eye defects, develop with
age and present in adulthood in mice (18,22,41). We therefore
performed a PBA treatment from conception to investigate if
targeting ER stress can prevent adult disease. We focused on
ICH as it underlies the cerebrovascular pathologies caused by
COL4A1/COL4A2 mutations, including porencephaly and small
vessel disease (10). This revealed that an oral preventative PBA
treatment reduces adult ICH due to Col4a1 glycine mutations.
These data are supported by a short term PBA treatment of
newborn pups (26) and mice harbouring a very severe splice
mutation (42). However, preventative treatment from birth or
early childhood will likely only be possible for rare familial
cases following molecular diagnosis/prenatal screening. For the
majority of cases treatment will and can only commence after
ICH andmolecular diagnosis has occurred, which also applies to
sporadic ICH in the general population for which collagen IV is a
risk factor (11–14). Interestingly and importantly, treating adult
mice for 1 month with PBA reduced total ICH, providing strong
evidence that targeting ER stress using chemical chaperones
has efficacy as a treatment for pre-existing ICH and COL4A1-
associated cerebrovascular disease.
A core requirement of personalized medicine is to delineate
patient groups for which a particular treatment is recommended
and those for which alternative approaches are required. Inves-
tigating the mode of action of treatments in light of the patho-
molecular disease mechanisms is therefore important. Besides
a chemical chaperone PBA can also act as a histone deacety-
lase inhibitor (43). The absence of altered collagen IV mRNA
levels provides evidence that PBA is acting through its chemical
chaperone activity. In addition, although PBA has been shown
to be able to reduce blood pressure in hypertension (44), it did
not affect blood pressure in our model, indicating its effects on
ICH is independent of blood pressure. PBA treatment reduced
ER stress and increased deposition of collagen IV in BMs, which
was associated with reduced mechanical strength of the BM.
This increased secretion in response to PBA treatment in vivo is
supported by data from other matrix diseases including Pierson
syndrome due to laminin B2 mutations (29) and Osteogenesis
Imperfecta caused by a Col1a1 mutation (45). As our model is
heterozygous for the causal mutation (18), similar to human
patients (39), we were not able to determine if the secreted colla-
gen is mutant or WT collagen. Similarly, the extent to which this
additional secreted collagen IV is integrated into the BM remains
to be determined. However, our data do indicate that promoting
collagen secretion via chemical chaperone treatment is counter-
indicative for COL4A1 pathologies caused by BM defects as PBA
treatment reduced the ability of BM to withstand mechanical
stress. In addition, the persistence of eye and renal defects
indicate that chemical chaperone treatment represents a poten-
tial therapeutic approach for patients that present only with
COL4A1-associated ICH but is not effective for those that also
exhibit renal or eye disease, establishing a criterion for patient
stratification. The apparent lack of effectivity for the eye phe-
notype may be related to the avascular nature of the adult lens,
which plays a key role in Col4a1 eye disease (46), as previous data
in cartilage (47) suggested that PBA is not effective for avascular
tissues. It will now also be important to establish if the lack of
effectivity for Col4a1 renal disease also applies to other kidney
pathologies due to mutations in BM components such as Alport
syndrome, where PBA reduced ER stress in cells with COL4A5
missense mutations (48).
The tissue-specific outcomes of our treatment also illustrate
the urgent need to increase our understanding of the molecular
disease mechanisms. Our previous work in the kidney showed
that Col4a1 Bowman’s capsule defects were associated with
matrix defects and the tubular disease with ER stress as it
occurred in the absence of BM defects and was associated with
chronic ER stress levels (22). The involvement of ER stress in the
eye disease has remained unclear with apparent conflicting data
(46,49). Given the reduced ER stress and ICH following treatment,
and persistence of matrix defects and kidney pathology, these
data provide significant evidence to the hypothesis that collagen
IVmutationsmay elicit cell and/or tissue-specific responses and
disease mechanisms, with varying contributions of ER stress
and/or matrix defects. In this case, it is tempting to suggest a
major role of matrix defect in the Bowman’s capsule pathology
and ER stress in cerebrovascular disease. However, while many
COL4A1/COL4A2 mutations in mice and patients cause matrix
defects and intracellular retention (7,18,25), not all mutations
elicit the same cellular response (24). For example,mice homozy-
gous for theCol4a1G498Vmutation,detected inHANACpatients,
are viable (21) in contrast to other glycine mutations in mice
(4,18,19), while other non-glycine mutations do not appear to
cause ER stress (24) and presumably act though matrix defects.
Given that our data lead us to suggest that chemical chaperone
treatmentmay not be warranted for COL4A1/4A2mutations that
act via matrix defects and do not cause ER stress, it is important
to delineate the actual contribution of intra- and extracellular
sequelae to disease pathogenesis and confirm treatment efficacy
across different Col4a1/Col4a2 mutations.
In conclusion, our data establish that reducing ER stress is a
therapeutic avenue for preventing and treating established adult
ICH but can be counter-indicative for pathologies due to extra-
cellular matrix defects as it reduces their ability to withstand
mechanical stress. This highlights the need for patient stratifica-
tion for such treatment approaches based on both their clinical
presentation and knowledge of the underlying mechanism of
their specific mutations.
Materials and Methods
Animal studies were performed in accordance with UK Home
Office regulations (Project license 70/8604). PBA (1 g/kg/day) (33)
was administered orally via drinking water (lifelong treatment),
or via gavage (1-month treatment). Animals were randomly
allocated to treatment/no-treatment group before genotyping
and development of overt phenotypes. Samples were labelled
numerically and did not display treatment/genotype status,
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blinding the researcher. Un-blinding occurred following com-
pletion of datasets.
Metabolic cage studies
Animals were individually housed and allowed to acclimatize
(24 h). Daily urine samples were collected and water consump-
tion measured.
Tail plethysmography was performed as previously described
(17).
Slit lamp analysis was performed as described (18).
MRI Analysis
MRI scanningwas performed on a 7Tesla Bruker Biospec scanner
(Bruker, Coventry, UK). A 72 cm volume resonator birdcage coil
was used for transmitting and four-channel phased array sur-
face coil for receiving the MRI signal. A gradient echo imaging
sequence was used to acquire T1 weighted images, with the
following parameters: 1.76 cm × 1.76 cm Field of View, 176 × 176
matrix, 100 μm × 100 μm, 14 coronal slices, thickness 0.5 mm,
repetition time 200 ms, echo time 3.3 ms, 8 averages, flip angle
30◦, total scan time 4 min 41 s. The 14 slices were acquired back
from the rhinal fissure, excluding the olfactory bulb and cere-
bellum. Images were acquired and reconstructed using Bruker
Paravision 5.1 software. Images were analyzed using ImageJ
software to calculate bleed volumes and number of bleeds.
Dermal BM analysis was performed by repeated application
and removal of autoclave tape on shaven dorsal skin. Following
dissection of skin areas, samples were processed for histology.
ImageJ was used tomeasure ratio of basement separation versus
length of epidermis, excluding hair follicles.
Histopathology
Tissues were fixed (10% neutral buffered formalin or 4%
paraformaldehyde) and paraffin embedded. Sections were
stained with haematoxylin–eosin or Perl’s Prussian blue using
standard protocols. For Perl’s Prussian blue staining to assess
ICH, image analysis was performed using ImageJ, colour
threshold plugin (50) to calculate the area of the section stained
positive for hemosiderin. A ratio of the bleed area versus tissue
section area represents bleed percentage. For each brain, six
sections of the midbrain, separated by 250 μm, were analysed
and the total area of the section stained positive for hemosiderin
was determined. Skin sections were stained with PAS using
standard protocols. Histopathology of the eye and kidney
section was performed using haematoxylin–eosin staining.
The eye section was scored based on (20). Briefly, scoring of
anterior segment defects was based on the presence/absence of
iridocorneal adhesion, ciliary body morphology (with three to
five foliations being considered normal), and presence/absence
of open Shlemm’s canal. Absence of iridocorneal adhesion,
three to five foliations of the ciliary body and presence of open
Shlemm’s canal were given a score of 1 whereas defects were
scored as 0. Mean ASD score was calculated per animal with
a maximum score of 6. Kidney sections were scored for the
presence of defects in Bowman’s capsule (including cuboidal
appearance of parietal epithelial cells, formation of multiple
cell layers) and glomerulocystic kidney disease (retraction of the
glomerular tuft, dilation of Bowman’s Space, circumference of
Bowman’s capsule measured using the segmented line tool in
ImageJ) as described (21). Statistical analysis was performed on
glomerulus/Bowman’s capsule data from > 10 random images
of three sections per animal of four mice.
EM analysis. Tissues were fixed in 2% glutaraldehyde in phos-
phate buffer and processed as described (34). EM thickness was
measured as described (22): measurements were taken every
∼800 nm in at least three animals with three to five structures
(e.g. Bowman’s capsule) analysed per animal. Statistical analysis
was performed using averages of individual structures.
qRT-PCR analysis was performed as previously described (17).
mRNA extracts were prepared using Tri Reagent followed by
cDNA synthesis using Affinity Script cDNA Synthesis Kit as per
manufacturer instructions. RT-PCR was performed in triplicate
using Power SYBR Green PCR Master Mix (Thermo Fisher Sci-
entific, Loughborough, UK) as per manufacturer instructions.
Analysis of mRNA levels was performed using the CT method
and was corrected for 18S ribosomal RNA.
Immunoblotting
Protein extracts were prepared in RIPA buffer containing
protease (Roche Applied Science, Welwyn Garden City, UK)
and phosphatase inhibitors (PhosStop Roche). Membranes
were blocked with 5% milk or bovine serum albumin (BSA)
before incubation with primary antibodies [BIP (1/10,000, BD
Transduction, Biosciences, Wokingham, UK), ATF4 (1/2500 Santa
Cruz, Heidelberg, Germany)], horseradish peroxidase conjugated
secondary antibodies (GE Healthcare, Little Chalfont, UK) and
development using chemiluminescense (Millipore,Watford, UK).
Protein levels were corrected for Coomassie staining of total
protein gels ran or protein stain onmembrane (Memcode, Pierce,
Thermo Fisher). Densitometry was performed using ImageJ.
Immunohistochemistry
Staining against collagen IV (H22 for Col4a2; 1/100) on cryosec-
tions was performed as described (22,34). Paraffin-embedded
sections underwent antigen retrieval using citrate buffer, were
incubated with primary antibodies against IBA1, then counter-
stained using Impress DAB kit (Vector Laboratories, Peterbor-
ough, UK). Images were captured using a Axiocam microscope
and Zen (Zeiss, Cambridge, UK) imaging software.
Statistical analysis (Graphpad Prism) was done by unpaired stu-
dent’s t-test, chi-square or one-way ANOVA with post hoc analy-
sis.
Supplementary Material
Supplementary Material is available at HMG online.
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